
CHICAGO — The suspense will end Friday when results from four highly anticipated clinical trials of nivolumab and pembrolizumab will be released at the American Society of Clinical Oncology meeting.
Both drugs are already-available programmed death inhibitors, and curiosity has been building about early clinical trials of nivolumab (Opdivo, Bristol-Myers Squibb Company) in advanced liver disease and pembrolizumab (Keytruda, Merck) in head and neck cancer.
The Medscape Oncology news team is traveling today to Chicago and will report the findings and all the latest news from McCormick Place.
Among the highlights on Friday will be details from the phase 3 trial of nivolumab in non-small cell lung cancer. Topline results released in January quickly led to the approval of the first immunotherapy for lung cancer by the US Food and Drug Administration.
© 2015 WebMD, LLC
Send comments and news tips to news@medscape.net.
Cite this: The Big Four at ASCO Friday - Medscape - May 28, 2015.
Comments